Drug intelligence / Profile preview

poly-l-lysine G2 + vitamin C + poly-l-lysine G3 + vitamin A

Development stage
Preclinical
Lead developer
Dermabel Cosmetics
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Peptides, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Topical
01

Overview

This is a combination dermocosmetic formulation containing second-generation poly-L-lysine dendrigraft (poly-l-lysine G2), third-generation poly-L-lysine dendrigraft (poly-l-lysine G3), vitamin C (ascorbic acid), and vitamin A. Poly-L-lysines act as biocompatible, biodegradable carriers that enhance the stability, penetration, and efficacy of vitamins in topical applications. Vitamin C is known for its role in collagen synthesis, antioxidant activity, and skin barrier protection but is highly unstable; complexing with poly-L-lysines significantly increases its liposolubility and stability against oxidation. Vitamin A regulates Langerhans cells and supports skin repair. The combination has demonstrated significant improvements in atopic dermatitis symptoms—reducing erythema, dryness, pruritus—and improving overall skin hydration without notable adverse effects. The formulation leverages the synergistic properties of these ingredients to provide enhanced moisturization, anti-inflammatory effects, improved tissue repair/regeneration, and better patient tolerance compared to traditional therapies[1][2][5].

02

Targets

Negatively charged cell surface components and extracellular matrix proteinsRXRA (Retinoid X receptor alpha)RARA (Retinoic acid receptor alpha)P4H (Prolyl 4-hydroxylase subunit alpha-3)

Beyond the preview

Go deeper on poly-l-lysine G2 + vitamin C + poly-l-lysine G3 + vitamin A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on poly-l-lysine G2 + vitamin C + poly-l-lysine G3 + vitamin A.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call